GlassScriptPhysician profile
John W Tyznik
NPI 1811964786
$8,739.60
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,961 · 2020: $1,475 · 2021: $1,936 · 2022: $1,915 · 2023: $1,381 · 2024: $71.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,452.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,195.81 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $1,026.50 | 2019-2023 | Vraylar, Ubrelvy, Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $567.27 | 2019-2023 | Ofev, Jardiance |
| Janssen Pharmaceuticals, INC | $565.74 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $512.48 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $482.10 | 2019-2023 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $476.42 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $440.91 | 2019-2023 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $365.22 | 2019-2023 | Prolia, Evenity, Otezla |
| Sanofi-Aventis U.S. LLC | $299.91 | 2019-2023 | |
| Pfizer INC. | $253.24 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $248.75 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $210.84 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $198.37 | 2019-2023 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.17 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tyznik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.